Sana Biotechnology closed the sale of over 3.35 million shares, raising approximately $86.3 million in its public offering.
Quiver AI Summary
Sana Biotechnology, Inc. announced the completion of its public offering, selling 3,358,208 shares of common stock at $3.35 per share, resulting in gross proceeds of approximately $86.3 million. This sale comes after the exercise of the underwriters' option to purchase additional shares related to an offering that closed on August 8, 2025. Major financial institutions including Morgan Stanley and Goldman Sachs acted as joint book-running managers for the offering, which was conducted under a previously filed SEC registration statement. The final prospectus for the offering can be accessed for free through the SEC’s website or requested from the involved financial institutions. The announcement clarifies that it does not constitute a solicitation or offer to sell securities in any jurisdiction where such actions would be unlawful.
Potential Positives
- Sana Biotechnology successfully closed the sale of over 3.3 million shares, demonstrating strong interest and demand from investors.
- The offering generated approximately $86.3 million in gross proceeds, providing significant capital to further the company's mission of developing engineered cell therapies.
- The sale followed the exercise of the underwriters' option, indicating confidence from financial institutions in Sana's future prospects.
Potential Negatives
- The price per share of $3.35 may indicate reduced investor confidence, especially if previous valuations were higher, signaling potential market concerns about the company's future.
- Issuing a large number of shares can dilute existing shareholders' ownership and may lead to dissatisfaction among current investors.
- The reliance on public offerings for funding may suggest a lack of sufficient cash flow or revenue generation capabilities, which could raise concerns about the company's financial health.
FAQ
What was the price per share in Sana's recent offering?
The price per share in Sana's recent offering was $3.35.
How many shares were sold in this public offering?
A total of 3,358,208 shares were sold in this public offering.
What were the total proceeds from the offering?
The total gross proceeds from the offering were approximately $86.3 million.
Who were the joint book-running managers for the offering?
Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen acted as joint book-running managers.
Where can I access the final prospectus for the offering?
The final prospectus can be accessed for free on the SEC's website at www.sec.gov.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SANA Hedge Fund Activity
We have seen 74 institutional investors add shares of $SANA stock to their portfolio, and 104 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS removed 5,449,035 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $14,875,865
- STATE STREET CORP removed 2,632,409 shares (-47.9%) from their portfolio in Q2 2025, for an estimated $7,186,476
- BOXER CAPITAL MANAGEMENT, LLC removed 1,545,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,595,600
- CORIENT PRIVATE WEALTH LLC added 824,505 shares (+264.7%) to their portfolio in Q2 2025, for an estimated $2,250,898
- AQR CAPITAL MANAGEMENT LLC added 783,217 shares (+136.7%) to their portfolio in Q2 2025, for an estimated $2,138,182
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 702,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,916,460
- MORGAN STANLEY added 654,131 shares (+79.2%) to their portfolio in Q2 2025, for an estimated $1,785,777
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SANA Analyst Ratings
Wall Street analysts have issued reports on $SANA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 07/03/2025
- JMP Securities issued a "Market Outperform" rating on 06/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/24/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/18/2025
- Jefferies issued a "Buy" rating on 03/14/2025
To track analyst ratings and price targets for $SANA, check out Quiver Quantitative's $SANA forecast page.
$SANA Price Targets
Multiple analysts have issued price targets for $SANA recently. We have seen 5 analysts offer price targets for $SANA in the last 6 months, with a median target of $7.0.
Here are some recent targets:
- Maxwell Skor from Morgan Stanley set a target price of $12.0 on 07/03/2025
- Reni Benjamin from JMP Securities set a target price of $5.0 on 06/24/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $11.0 on 04/24/2025
- Reni Benjamin from Citizens Capital Markets set a target price of $5.0 on 03/18/2025
- Roger Song from Jefferies set a target price of $7.0 on 03/14/2025
Full Release
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale of 3,358,208 shares of its common stock at a price to the public of $3.35 per share, pursuant to the exercise in full of the underwriters’ option to purchase additional shares in connection with Sana’s previously announced underwritten public offering, which closed on August 8, 2025. All of the shares were sold by Sana. Total gross proceeds from the offering, including the full exercise of the underwriters’ option, were approximately $86.3 million, before deducting underwriting discounts and commissions and other offering expenses.
Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen acted as joint book-running managers for the offering.
The offering was made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with and declared effective by the SEC. Sana has filed with the SEC the final prospectus supplement and accompanying prospectus relating to the offering. These documents can be accessed for free through the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at [email protected] ; Goldman Sachs & Co. LLC, Attn: Prospectus Department, at 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at [email protected] ; BofA Securities, Attn: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at [email protected] ; or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at [email protected] .
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.
Investor Relations & Media:
Nicole Keith
[email protected]
[email protected]
